Inhibiting GSK3β with a GSK3β inhibitor in TAMs reduces the proliferation, migration and invasion of HCC cells in vitro and inhibits tumour growth in vivo improving the sensitivity of the anti-PD1 therapy. The gene discussed is GSK3B; the disease is neoplasm.